(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: Justin Gover, CEO of GW Pharmaceuticals, on the drug pipeline for the UK- based company which has been developing drug treatments derived from cannabis for decades.

Lyft Earnings Miss Estimates After Global Expansion Push
25:56

Wall Street Poised for Bonus Increases in ‘Year of the Bank’
26:24

AMD Soars as AI Demand Fuels Better-Than-Expected Sales Outlook
20:33